Technology | 2020.07.29
Catalent Enters into Strategic Partnership with Editas Medicine to Support Gene Editing Medicine Pipeline
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that they have entered into a strategic partnership whereby Catalent will provide support for the development, manufacturing, and clinical supply of Editas Medicine’s current and future portfolio of in vivo CRISPR medicines and engineered cell medicines.
(PRWeb July 29, 2020)
Read the full story at https://www.prweb.com/releases/catalent_enters_into_strategic_partnership_with_editas_medicine_to_support_gene_editing_medicine_pipeline/prweb17287863.htm
For more information, please visit
https://www.prweb.com/releases/catalent_[...]ine_pipeline/prweb17287863.htm
